A method to effectively treat the adverse events of ingested orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel and ingesting an enteric coated activated charcoal member to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.
